Selling a veterinary practice or group in the UK

You own a UK veterinary practice or group worth between £5M and £50M in enterprise value. A single-site small animal practice at the upper end of the segment. A regional first-opinion group of three to fifteen sites. A mixed or equine practice with strong client base depth. A specialist referral practice in oncology, orthopaedics, neurology or dermatology.

The buyer pool in UK vet M&A has evolved materially over the last 18 months. Several large PE-backed and corporate consolidators remain actively acquiring, but the CMA market investigation has changed both the pace and the diligence intensity. We track this carefully and advise owners on how it affects timing, buyer composition and process design. Specialist referral practices attract a separate, narrower but well-funded buyer pool again, including specialist referral consolidators and overseas strategics.

We engage 12 to 24 months before a target exit. In vet specifically, the regulatory environment under the CMA review and the importance of vet retention make the longer preparation window more material than ever. Practices that go to market without addressing vet retention and CMA-driven diligence expectations consistently underperform.

This is not the right fit if your practice is below £5M EV, or if vet retention is in active flux. In both cases we will be straight about why. It is also not the right fit if you are committed to a specific approach already on the table; that is execution support, which fits a different mandate.

Buyers of veterinary practices focus on nine things: vet retention, site economics, client base depth, specialist accreditation, CMA-related diligence, subscription and preventive care penetration, diagnostic and technology capability, property structure and freehold mix, and insurance penetration and average client value. Each has become sharper under the CMA review environment.

Vet retention first. The headline diligence concern across every buyer in this sector. Tenure data, salary benchmarks against the regional market, restrictive covenants, billings per vet, and any post-sale lock-in arrangements all sit at the top of the buyer pack. With the CMA review highlighting workforce dynamics, this has tightened further. Practices where senior vets have not been engaged with the transaction story consistently re-trade at completion.

Site economics second. Per-site EBITDA, revenue per FTE vet, client retention, average spend per client, and the proportion of revenue from preventive care plans. Multi-site groups where individual site performance varies widely are valued on the weaker sites.

Client base depth third. Active client count, client tenure distribution, revenue per client, and the proportion of revenue on subscription / health plans. A strong subscription book materially supports premium pricing because of revenue visibility.

Specialist accreditation fourth. RCVS practice standards accreditation level, specialist clinical accreditations, advanced practitioner status of senior team. These act as barriers to entry and support premium multiples, especially for specialist referral practices.

CMA-related diligence fifth. The CMA market investigation has introduced new diligence threads: pricing transparency, client communication standards, ownership disclosure, choice and switching. Buyers expect to see practices operating to the standards the CMA is establishing rather than the standards a previous regulatory environment tolerated. Practices that align ahead of time outperform.

Subscription and preventive care penetration sixth. The proportion of active clients enrolled on subscription plans (Healthy Pet Club, Complete Care and equivalents) is a headline metric for every consolidator. Practices with 25%+ of clients on active subscriptions attract meaningful premium because of revenue visibility, client retention and cross-sell economics. Building out subscription penetration in the 12 to 18 months before going to market is one of the highest-return preparation items available to first-opinion practices.

Diagnostic and technology capability seventh. Digital radiography, in-house ultrasound, CT where present, in-house lab capability, and PMS (practice management system) sophistication all factor into buyer diligence. Practices running on modern cloud PMS (ezyVet, Provet Cloud, RxWorks Cloud) integrate meaningfully more easily into consolidator platforms than those on legacy on-premise systems, and consolidators price that integration cost into the multiple.

Property structure and freehold mix eighth. Freehold-owned sites, particularly outside London and the South East, attract additional interest from property-led investors alongside operating buyers. We help owners decide whether to retain freehold with a lease-back to the buyer, sell the property separately, or sell as a bundle, the choice frequently affects total proceeds by more than the operating-side negotiation does.

Insurance penetration and average client value ninth. Practices with high insurance penetration in the client base (30%+ of pets insured), documented cross-sell into food, medicines and preventive care, and above-average spend per active client materially outperform in valuation. Buyers use these metrics as a proxy for underlying client-relationship quality: sticky, high-value clients survive owner changes.

Active corporate and PE-backed consolidators including CVS Group, IVC Evidensia, VetPartners, Linnaeus Group, Medivet and White Cross Vets are still acquiring UK veterinary practices, but at a more disciplined pace under CMA scrutiny. UK veterinary M&A has moved through a distinct phase change in 2024 to 2026 following the Competition and Markets Authority (CMA) market investigation into the sector. Below is a snapshot of what is currently visible in the market.

**Active corporate and PE-backed consolidators.** CVS Group (LSE-listed), IVC Evidensia (EQT-backed), VetPartners (BC Partners), Linnaeus Group (Mars Petcare), Medivet (Silverlake), White Cross Vets (Independent Vetcare Group), My Family Vets and various regional roll-ups all remain active, though at a more disciplined pace under CMA scrutiny, with sharper focus on strategic fit rather than volume acquisition.

**Multiples.** First-opinion small animal practices trade in the 7 to 10x adjusted EBITDA range for single sites; groups of four or more sites reach 10 to 14x; specialist referral centres (oncology, orthopaedics, cardiology, neurology, exotic) command 12 to 16x depending on clinical profile and clinician retention. Mixed and equine practices trade at the lower end of first-opinion ranges given narrower buyer pools.

**Specialist referral M&A.** Sub-segment referral (oncology, orthopaedics, neurology, dermatology) attracts a narrower but internationally active buyer pool. Overseas strategics, particularly Nordic and North American referral platforms, have shown consistent interest in UK referral centres with strong clinical profiles and defensible geographic catchments.

**CMA impact on process.** The CMA's interim measures on price transparency, ownership disclosure and client communication have not closed the market but have raised the bar on preparation. Practices arriving at diligence without CMA-aligned governance in place consistently see two to four weeks of additional friction. Practices that align ahead of time complete faster and on stronger terms.

**Sub-sector shifts.** Emergency and critical care (ECC) groups have been actively targeted by both PE and strategic buyers over the last 18 months. Standalone imaging centres and specialist dental (veterinary dentistry) referral practices have also seen increased buyer attention. First-opinion multi-site groups in geographies with limited existing consolidator density remain the most competitively bid segment.

**Timing.** Owners considering an exit in the next 18 to 24 months benefit from starting readiness work now: CMA alignment, subscription penetration build-out, vet retention arrangements and PMS modernisation all have 12+ month lead times. Practices that wait until they receive an unsolicited approach consistently leave value on the table.

A veterinary practice is sold through Mastella's senior-led six-stage process, shaped by three things: CMA-related diligence on a longer clock and wider scope, vet engagement built into the process design from the start, and buyer mapping segmented by consolidator and by specialist referral.

CMA-related diligence sits on a longer clock and a wider scope than vet practices have historically run. We design the process around this rather than discovering the implications late. Where pricing transparency, ownership disclosure or client communication standards need attention, the readiness phase is the right time to address them.

Vet engagement is structured into the process design from the start. We work with owners on how and when senior vets are told about the transaction, the post-sale lock-in arrangements, and any equity or retention arrangements that need to be in place. The single fastest way to lose a veterinary deal at completion is to fail to engage the team properly in advance.

Buyer mapping is segmented and changing fast. Active consolidators differ in CMA-readiness, size appetite, geographic preference, and integration intensity. Specialist referral practices attract an additional, narrower buyer pool again. Our buyer mapping is supported by our proprietary technology layer for surfacing acquirer signals from licensed market data. See the healthcare services pillar for context and dental practices for the closest adjacent niche.